MicuRx(SH:688373) Zhong Guo Jing Ji Wang·2025-08-20 03:14Core Viewpoint - Mengke Pharmaceutical (688373.SH) reported a revenue of 66.97 million yuan for the first half of 2025, marking a year-on-year increase of 10.26%, while the net profit attributable to shareholders was a loss of 139 million yuan, an improvement from a loss of 201 million yuan in the same period last year [1][2]. Financial Performance - Revenue for the first half of 2025 was 66,969,753.09 yuan, up from 60,738,238.45 yuan in the previous year, reflecting a growth of 10.26% [2]. - The net profit attributable to shareholders was -138,674,492.55 yuan, compared to -201,304,246.81 yuan in the same period last year, indicating a reduction in losses [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -143,358,346.31 yuan, improved from -211,520,217.94 yuan year-on-year [2]. - The net cash flow from operating activities was -120,704,678.78 yuan, an improvement from -229,023,837.10 yuan in the previous year [2]. Historical Performance - Mengke Pharmaceutical has reported losses for three consecutive years since its IPO in August 2022, with revenues of 48.21 million yuan in 2022, 90.78 million yuan in 2023, and projected 130 million yuan in 2024 [3]. - The net profit attributable to shareholders for the years 2022, 2023, and projected for 2024 were -220 million yuan, -421 million yuan, and -440 million yuan respectively [3].